Get started
CRISPR Therapeutics AGCRISPR Therapeutics AGCRISPR Therapeutics AG

CRISPR Therapeutics AG

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CRSP chart


Full chart

CRSP upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.43 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.80 USD
Net income (FY)
‪−153.61 M‬ USD
Revenue (FY)
‪371.21 M‬ USD
Shares float
‪81.47 M‬
Beta (1Y)
1.93

Employees


Employees (FY)
407
Change (1Y)
−51 −11.14%
Revenue / Employee (1Y)
‪912.05 K‬ USD
Net income / Employee (1Y)
‪−377.42 K‬ USD

About CRISPR Therapeutics AG


Sector
Health Technology
Industry
Biotechnology
CEO
Samarth Kulkarni
Website
crisprtx.com
Headquarters
Zug
Founded
2013
ISIN
CH0334081137
FIGI
BBG00DBBGRX1
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CRSP news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CRSP is 52.10 USD — it has increased by 2.29% in the past 24 hours. Watch CRISPR Therapeutics AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CRISPR Therapeutics AG stocks are traded under the ticker CRSP.
CRSP stock has risen by 8.63% compared to the previous week, the month change is a 15.08% rise, over the last year CRISPR Therapeutics AG has showed a −5.43% decrease.
We've gathered analysts' opinions on CRISPR Therapeutics AG future price: according to them, CRSP price has a max estimate of 199.00 USD and a min estimate of 30.00 USD. Watch CRSP chart and read a more detailed CRISPR Therapeutics AG stock forecast: see what analysts think of CRISPR Therapeutics AG and suggest that you do with its stocks.
CRSP reached its all-time high on Jan 15, 2021 with the price of 220.20 USD, and its all-time low was 11.63 USD and was reached on Feb 15, 2017. View more price dynamics on CRSP chart.
See other stocks reaching their highest and lowest prices.
CRSP stock is 3.52% volatile and has beta coefficient of 1.93. Track CRISPR Therapeutics AG stock price on the chart and check out the list of the most volatile stocks — is CRISPR Therapeutics AG there?
Today CRISPR Therapeutics AG has the market capitalization of ‪4.42 B‬, it has decreased by −0.04% over the last week.
Yes, you can track CRISPR Therapeutics AG financials in yearly and quarterly reports right on TradingView.
CRISPR Therapeutics AG is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
CRSP earnings for the last quarter are −1.01 USD per share, whereas the estimation was −1.38 USD resulting in a 27.06% surprise. The estimated earnings for the next quarter are −1.26 USD per share. See more details about CRISPR Therapeutics AG earnings.
CRISPR Therapeutics AG revenue for the last quarter amounts to ‪602.00 K‬ USD, despite the estimated figure of ‪6.57 M‬ USD. In the next quarter, revenue is expected to reach ‪9.08 M‬ USD.
CRSP net income for the last quarter is ‪−85.94 M‬ USD, while the quarter before that showed ‪−126.41 M‬ USD of net income which accounts for 32.01% change. Track more CRISPR Therapeutics AG financial stats to get the full picture.
No, CRSP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 407.00 employees. See our rating of the largest employees — is CRISPR Therapeutics AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR Therapeutics AG EBITDA is ‪−313.02 M‬ USD, and current EBITDA margin is −54.61%. See more stats in CRISPR Therapeutics AG financial statements.
Like other stocks, CRSP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR Therapeutics AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR Therapeutics AG technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR Therapeutics AG stock shows the sell signal. See more of CRISPR Therapeutics AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.